HLA-C and neoplasm: Several studies have highlighted the connection between epigenetic drugs and tumor immunogenic cell death, suggesting that epigenetic modulators can regulate the tumor microenvironment (TME) and the immune cycle by enhancing the expression of tumor-associated antigens, MHC molecules, and antigen-presenting cells (APCs), thus promoting immune cell priming and tumor antigen recognition 30.